Allogene Therapeutics (ALLO) Interest Expenses (2018 - 2026)
Allogene Therapeutics (ALLO) posted Interest Expenses of $102.7 million for Q1 2026, up 746.02% sequentially from $12.1 million in Q4 2025, and up 629.38% YoY from $14.1 million in Q1 2025.
Allogene Therapeutics (ALLO) Interest Expenses (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Interest Expenses for 9 years, with the latest figure at $102.7 million in Q1 2026.
- Quarterly Interest Expenses rose 629.38% year-over-year to $102.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $102.7 million (up 629.38% YoY) and the FY2025 annual result came in at $12.9 million, down 97.1% from the prior year.
- Interest Expenses improved to $102.7 million in Q1 2026 per ALLO's latest filing, from $12.1 million in the prior quarter.
- Over five years, Interest Expenses peaked at $143.4 million in Q3 2022 and troughed at -$6.0 million in Q4 2023.
- A 5-year average of $34.4 million and a median of $14.1 million in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses slumped 186.96% in 2023, then jumped 14885.19% in 2025.
- Over 5 years, Interest Expenses stood at $6.9 million in 2022, then tumbled by 186.96% to -$6.0 million in 2023, then jumped by 101.35% to $81000.0 in 2024, then surged by 14885.19% to $12.1 million in 2025, then soared by 746.02% to $102.7 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $102.7 million, $12.1 million, and $24.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | 99.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 99.40 Mn |
| Jun 30, 2026 | 99.40 Mn |
| Mar 31, 2026 | 102.69 Mn |
| Mar 31, 2026 | 102.69 Mn |
| Dec 31, 2025 | 12.14 Mn |
| Dec 31, 2025 | 12.14 Mn |
| Sep 30, 2025 | 24.31 Mn |
| Sep 30, 2025 | 24.31 Mn |
| Jun 30, 2025 | 25.65 Mn |
| Jun 30, 2025 | 25.65 Mn |
| Mar 31, 2025 | 14.08 Mn |
| Mar 31, 2025 | 14.08 Mn |
| Dec 31, 2024 | 81,000.00 |
| Dec 31, 2024 | 81,000.00 |
| Sep 30, 2024 | 13.61 Mn |
| Sep 30, 2024 | 13.61 Mn |
| Jun 30, 2024 | 125.54 Mn |
| Jun 30, 2024 | 125.54 Mn |
| Mar 31, 2024 | 13.61 Mn |
| Mar 31, 2024 | 13.61 Mn |